Analyst firms · Raymond James · MIRM
Raymond James MIRM price target and rating history
Mirum Pharmaceuticals Inc. (MIRM) · Health Care
Raymond James rates Mirum Pharmaceuticals Inc. (MIRM) Strong Buy with a $74 price target, as of its latest action on Mar 11, 2022. It has published 4 rating actions on MIRM since September 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a MIRM price target in the last 12 months, the median target is $145.
- Current rating
- Strong Buy
- Price target
- $74
- Median target, all firms
- $145
- Actions on MIRM
- 4
Raymond James price target on MIRM
Every Raymond James rating on MIRM
- Mar 11, 2022
- Jan 12, 2022
- Sep 30, 2021
- Sep 14, 2021
How other firms rate MIRM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $145 | Jun 2, 2026 |
| Wolfe Research | Outperform | $145 | May 19, 2026 |
| RBC Capital Markets | Outperform | $130 | Feb 18, 2026 |
Questions about Raymond James and MIRM
- What is Raymond James's price target for MIRM?
- Raymond James's latest stated price target for Mirum Pharmaceuticals Inc. (MIRM) is $74, from its action on Mar 11, 2022.
- What is Raymond James's rating on MIRM?
- Raymond James rates MIRM Strong Buy, a bullish rating, as of Mar 11, 2022.
- When did Raymond James last change its view on MIRM?
- On Mar 11, 2022, Raymond James raises its price target to $74 from $70, keeps Strong Buy.
- How does Raymond James's MIRM target compare with other analysts?
- Across 3 firms with a MIRM price target in the last 12 months, the median target is $145.
More MIRM rating histories
All Raymond James ratingsMIRM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.